Literature DB >> 31452083

MicroRNA-532 exerts oncogenic functions in t(4;14) multiple myeloma by targeting CAMK2N1.

Kaihong Xu1, Xuezhen Hu2, Laifang Sun2, Qingyue Liang3, Guifang Ouyang4, Yanli Zhang4, Qitian Mu4, Xiao Yan4.   

Abstract

Multiple myeloma (MM) is a plasma cell neoplasm which is characterized by widespread genetic heterogeneity. The MMs with t(4;14) translocation exhibit poor outcomes. However, the mechanism underlying has not been well dissected. Our study aimed to identify key microRNA involved in the oncogenesis of t(4;14) MM. We here performed an integrated analysis to screen important regulators in the pathogenesis of t(4;14) MM. We used real-time quantitative polymerase chain reaction and western blotting to evaluate the mRNA and protein expression of the indicated microRNA or protein. Cell proliferation assay, colony formation assay, and transwell assay were used to examine the cell growth and metastasis. More importantly, the tumor growth and metastasis were analyzed in nude mice injected with MM cells. The integrated analysis indicated that miR-532 functioned as a pivotal regulator in t(4;14) MM. miR-532 was upregulated in t(4;14) MMs and promotes cell growth and metastasis in vitro and in vivo. Notably, though combing bioinformatics analysis and functional assays, CAMK2N1 was revealed as a functional target of miR-532 in MM cells. CAMK2N1 plays an anti-proliferative and anti-migration role in MM cells, and miR-532 exerts its oncogenic role though inhibiting CAMK2N1 expression in MMs. miR-532 promotes cell proliferation and invasion in t(4;14) MMs by targeting CAMK2N1. Our study, thus, provides possible targets for t(4;14) MM therapy.

Entities:  

Keywords:  CAMK; Multiple myeloma; miR-532; t(4;14)

Mesh:

Substances:

Year:  2019        PMID: 31452083     DOI: 10.1007/s13577-019-00276-y

Source DB:  PubMed          Journal:  Hum Cell        ISSN: 0914-7470            Impact factor:   4.174


  34 in total

1.  Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets.

Authors:  Benjamin P Lewis; Christopher B Burge; David P Bartel
Journal:  Cell       Date:  2005-01-14       Impact factor: 41.582

Review 2.  MicroRNA signatures in human cancers.

Authors:  George A Calin; Carlo M Croce
Journal:  Nat Rev Cancer       Date:  2006-11       Impact factor: 60.716

3.  A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia.

Authors:  George Adrian Calin; Manuela Ferracin; Amelia Cimmino; Gianpiero Di Leva; Masayoshi Shimizu; Sylwia E Wojcik; Marilena V Iorio; Rosa Visone; Nurettin Ilfer Sever; Muller Fabbri; Rodolfo Iuliano; Tiziana Palumbo; Flavia Pichiorri; Claudia Roldo; Ramiro Garzon; Cinzia Sevignani; Laura Rassenti; Hansjuerg Alder; Stefano Volinia; Chang-gong Liu; Thomas J Kipps; Massimo Negrini; Carlo M Croce
Journal:  N Engl J Med       Date:  2005-10-27       Impact factor: 91.245

4.  International staging system for multiple myeloma.

Authors:  Philip R Greipp; Jesus San Miguel; Brian G M Durie; John J Crowley; Bart Barlogie; Joan Bladé; Mario Boccadoro; J Anthony Child; Herve Avet-Loiseau; Jean-Luc Harousseau; Robert A Kyle; Juan J Lahuerta; Heinz Ludwig; Gareth Morgan; Raymond Powles; Kazuyuki Shimizu; Chaim Shustik; Pieter Sonneveld; Patrizia Tosi; Ingemar Turesson; Jan Westin
Journal:  J Clin Oncol       Date:  2005-04-04       Impact factor: 44.544

5.  Accumulation of miR-155 and BIC RNA in human B cell lymphomas.

Authors:  Peggy S Eis; Wayne Tam; Liping Sun; Amy Chadburn; Zongdong Li; Mario F Gomez; Elsebet Lund; James E Dahlberg
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-28       Impact factor: 11.205

6.  Molecular classification of multiple myeloma: a distinct transcriptional profile characterizes patients expressing CCND1 and negative for 14q32 translocations.

Authors:  Luca Agnelli; Silvio Bicciato; Michela Mattioli; Sonia Fabris; Daniela Intini; Donata Verdelli; Luca Baldini; Fortunato Morabito; Vincenzo Callea; Luigia Lombardi; Antonino Neri
Journal:  J Clin Oncol       Date:  2005-08-29       Impact factor: 44.544

7.  MicroRNA signature predicts survival and relapse in lung cancer.

Authors:  Sung-Liang Yu; Hsuan-Yu Chen; Gee-Chen Chang; Chih-Yi Chen; Huei-Wen Chen; Sher Singh; Chiou-Ling Cheng; Chong-Jen Yu; Yung-Chie Lee; Han-Shiang Chen; Te-Jen Su; Ching-Cheng Chiang; Han-Ni Li; Qi-Sheng Hong; Hsin-Yuan Su; Chun-Chieh Chen; Wan-Jiun Chen; Chun-Chi Liu; Wing-Kai Chan; Wei J Chen; Ker-Chau Li; Jeremy J W Chen; Pan-Chyr Yang
Journal:  Cancer Cell       Date:  2008-01       Impact factor: 31.743

8.  Upregulation of translational machinery and distinct genetic subgroups characterise hyperdiploidy in multiple myeloma.

Authors:  Luca Agnelli; Sonia Fabris; Silvio Bicciato; Dario Basso; Luca Baldini; Fortunato Morabito; Donata Verdelli; Katia Todoerti; Giorgio Lambertenghi-Deliliers; Luigia Lombardi; Antonino Neri
Journal:  Br J Haematol       Date:  2007-02       Impact factor: 6.998

Review 9.  Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets.

Authors:  Teru Hideshima; Constantine Mitsiades; Giovanni Tonon; Paul G Richardson; Kenneth C Anderson
Journal:  Nat Rev Cancer       Date:  2007-08       Impact factor: 60.716

10.  Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma.

Authors:  Robert A Kyle; Ellen D Remstein; Terry M Therneau; Angela Dispenzieri; Paul J Kurtin; Janice M Hodnefield; Dirk R Larson; Matthew F Plevak; Diane F Jelinek; Rafael Fonseca; Lee Joseph Melton; S Vincent Rajkumar
Journal:  N Engl J Med       Date:  2007-06-21       Impact factor: 91.245

View more
  3 in total

1.  Depletion of circ_0007841 inhibits multiple myeloma development and BTZ resistance via miR-129-5p/JAG1 axis.

Authors:  Yan Wang; Quande Lin; Chunge Song; Ruojin Ma; Xiaojie Li
Journal:  Cell Cycle       Date:  2020-11-01       Impact factor: 4.534

2.  CAMK2N1/RUNX3 methylation is an independent prognostic biomarker for progression-free and overall survival of platinum-sensitive epithelial ovarian cancer patients.

Authors:  Karolin Heinze; Matthias Rengsberger; Mieczyslaw Gajda; Lars Jansen; Linea Osmers; Leticia Oliveira-Ferrer; Barbara Schmalfeldt; Matthias Dürst; Norman Häfner; Ingo B Runnebaum
Journal:  Clin Epigenetics       Date:  2021-01-22       Impact factor: 6.551

3.  NcRNA-mediated upregulation of CAMK2N1 is associated with poor prognosis and tumor immune infiltration of gastric cancer.

Authors:  Kaipeng Peng; Xiangqing Ren; Qian Ren
Journal:  Front Genet       Date:  2022-08-25       Impact factor: 4.772

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.